Autopsy case: Pathological complete response in an advanced lung cancer patient with severe immune related adverse events and COVID-19

IF 2.4 Q2 RESPIRATORY SYSTEM Respiratory investigation Pub Date : 2024-03-22 DOI:10.1016/j.resinv.2024.03.002
Ryoma Moriya , Naoki Kamihata , Yoshikazu Niwa , Hisashi Kako , Hideaki Takahashi , Yutaro Kimura , Yoshiko Shigeyasu , Tetsuya Tsukamoto , Naozumi Hashimoto , Kazuyoshi Imaizumi
{"title":"Autopsy case: Pathological complete response in an advanced lung cancer patient with severe immune related adverse events and COVID-19","authors":"Ryoma Moriya ,&nbsp;Naoki Kamihata ,&nbsp;Yoshikazu Niwa ,&nbsp;Hisashi Kako ,&nbsp;Hideaki Takahashi ,&nbsp;Yutaro Kimura ,&nbsp;Yoshiko Shigeyasu ,&nbsp;Tetsuya Tsukamoto ,&nbsp;Naozumi Hashimoto ,&nbsp;Kazuyoshi Imaizumi","doi":"10.1016/j.resinv.2024.03.002","DOIUrl":null,"url":null,"abstract":"<div><p>A 51-year-old man with advanced lung cancer underwent chemotherapy including an immune checkpoint inhibitor (ICI). Subsequently, he developed ICI-related pneumonitis and colitis, followed by a ten-month treatment course of high doses of steroids. An infection with the SARS-CoV-2 Omicron BA.5 variant caused lethal respiratory failure. Autopsy examination revealed no evidence of viable lung cancer cells in the evaluated organs including the lungs, suggesting that pathological complete response (pCR) could be successfully achieved by ICI treatment in advanced lung cancer patients.</p><p>Recognizing steroid-resistant ICI-related adverse events as critical factors in severe COVID-19 emphasizes the need for appropriate assessment of ICI-induced pCR.</p></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory investigation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212534524000443","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

A 51-year-old man with advanced lung cancer underwent chemotherapy including an immune checkpoint inhibitor (ICI). Subsequently, he developed ICI-related pneumonitis and colitis, followed by a ten-month treatment course of high doses of steroids. An infection with the SARS-CoV-2 Omicron BA.5 variant caused lethal respiratory failure. Autopsy examination revealed no evidence of viable lung cancer cells in the evaluated organs including the lungs, suggesting that pathological complete response (pCR) could be successfully achieved by ICI treatment in advanced lung cancer patients.

Recognizing steroid-resistant ICI-related adverse events as critical factors in severe COVID-19 emphasizes the need for appropriate assessment of ICI-induced pCR.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
尸检病例:晚期肺癌患者病理完全应答,伴有严重免疫相关不良事件和 COVID-19
一名 51 岁的晚期肺癌患者接受了包括免疫检查点抑制剂(ICI)在内的化疗。随后,他患上了与 ICI 相关的肺炎和结肠炎,并接受了为期 10 个月的大剂量类固醇治疗。SARS-CoV-2 Omicron BA.5变种感染导致了致命的呼吸衰竭。尸检显示,在包括肺部在内的评估器官中没有发现存活的肺癌细胞,这表明晚期肺癌患者可以通过 ICI 治疗成功获得病理完全反应(pCR)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Respiratory investigation
Respiratory investigation RESPIRATORY SYSTEM-
CiteScore
4.90
自引率
6.50%
发文量
114
审稿时长
64 days
期刊最新文献
Association of constipation with the survival of patients with idiopathic interstitial pneumonias Importance of vaccines against respiratory infections in adults Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in patients with systemic rheumatic diseases receiving moderate-to high-dose glucocorticoids Lung cancer with comorbid interstitial pneumonia: Current situation and animal model development Refractory bilateral chylothorax and chylous ascites in a patient with systemic lupus erythematosus treated by pleuro-peritoneal and peritoneal-venous shunts along with cell-free and concentrated ascites re-infusion therapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1